October 26, 2022
Daiichi Sankyo said on October 25 that its FLT3 inhibitor quizartinib has obtained the US FDA’s priority review for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML). The agency has set its target action date for...read more